Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model
2011

HPV16 E7 Vaccine Induces Tumor Protection in Mice

Sample size: 42 publication 10 minutes Evidence: high

Author Information

Author(s): Petrone Linda, Ammendolia Maria G, Cesolini Armando, Caimi Stefano, Superti Fabiana, Giorgi Colomba, Di Bonito Paola

Primary Institution: Istituto Superiore di Sanità

Hypothesis

Can a recombinant HPV16 E7 protein induce an immune response and tumor protection without the use of adjuvants?

Conclusion

The study demonstrates that a particulate form of HPV16 E7 can induce tumor protection in mice without the need for adjuvants.

Supporting Evidence

  • Mice immunized with three doses of E7 showed full protection from tumor growth.
  • The E7 preparation induced a significant humoral and cell-mediated immune response.
  • The study utilized a well-established mouse tumor model for HPV16.

Takeaway

Researchers created a vaccine using a part of a virus that causes cancer and found that it can help mice fight off tumors without needing extra help.

Methodology

The E7 protein was expressed in E. coli, purified, and administered to mice in varying doses to evaluate immune response and tumor protection.

Potential Biases

Potential bias in the selection of animal models and the interpretation of immune response data.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

C57BL/6 female mice, aged 6-8 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-9-69

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication